Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesMarketing therapeutic precision: Potential facilitators and barriers to adoption of n-of-1 trials
Contemporary Clinical Trials , 08/24/09
Kravitz RL et al. – Researchers interested in expanding the appeal of n–of–1 trials will need to address these concerns by carefully explaining the approach, emphasizing the benefits, and minimizing the effort required of doctors and patients.
Related Articles
Mesenchymal Stem Cells for Therapeutic Purposes
Transplantation, 10/07/09
Relevance Score: 64%
Allos Therapeutics to Present at Upcoming Conferences in November
Allos Therapeutics, 11/11/09
Relevance Score: 45%
ImmunoGen, Inc. Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
ImmunoGen, Inc., 11/11/09
Relevance Score: 43%
Allos Therapeutics to Report Third Quarter 2009 Results on November 2009
Allos Therapeutics, 10/27/09
Relevance Score: 43%
Agonists and allosteric modulators of the Calcium Sensing Receptor and their therapeutic applications
Molecular Pharmacology, 10/02/09
Relevance Score: 43%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
Milatuzumab – a promising new immunotherapeutic agent
Expert Opinion on Investigational Drugs, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor